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Objective: It has long been evident that lifetime follow-up after endovascular aneurysm repair (EVAR) is necessary to
identify late complications. The purpose of this study is to test the hypothesis that late follow-up rates for EVAR in
routine practice are inferior to those reported from protocol-driven clinical trials, consequently contributing to avoidable
events associated with poor long-term outcome.
Methods: From February 1999 to December 2005, 302 EVARs were performed and eligible for follow-up. Of these, 47
were performed as part of an industry-sponsored clinical trial (study patients). Responsibility for follow-up was assigned
to a research nurse for study patients and to office clerical staff for nonstudy patients. Follow-up compliance was classified
as either frequent (<1 missed scheduled appointment) or incomplete (>2 missed scheduled appointments). Overall
survival and complication rates were analyzed.
Results: Of the 302 patients, 203 (67.2%) had frequent follow-up and 99 (32.8%) had incomplete follow-up. The mean
follow-upwas significantly better in the frequent follow-up group (34.7 22months) vs the incomplete follow-up group
(18.8  18.6 months, P < .001). The 5-year survival (63.9% frequent vs 64.0% incomplete), the 5-year reintervention
rate (22.3% frequent vs 10.8% incomplete), and incidence of known endoleak (14.8% frequent vs 9.1% incomplete) were
statistically similar in the two groups. The incidence of major adverse events, defined as events requiring urgent surgical
intervention, was significantly increased in the incomplete follow-up group (6.1% vs 0.5%; P  .006), with nearly half of
these patients dying perioperatively. There was no difference in measured outcomes for study patients compared with
nonstudy patients. However, mean follow-up was significantly longer for study patients vs nonstudy patients (44.8 
23.7 months vs 26.8  20.9 months; P < .001).
Conclusions: Follow-up surveillance after EVAR is less intense in practice environments outside of clinical trials. Patients
with incomplete follow-up have higher fatal complication rates than patients with frequent follow-up. These data expose
a potential under-appreciated limitation of EVAR, questioning whether the findings in clinical trials defining the efficacy
of EVAR can be routinely extrapolated to ordinary practice. ( J Vasc Surg 2007;46:434-41.)Since the original description by Drs Parodi, Palmaz,
and Barone in 1991, endovascular aneurysm repair
(EVAR) has progressively become the preferred method
of treatment for patients with abdominal aortic aneurysm
(AAA).1 A continued shortcoming of EVAR is endoleak,
a complication that occurs over the life of the graft in
25% to 47% of cases.2 Fortunately, endoleak is relatively
easy to diagnose and can usually be corrected by endo-
vascular techniques. The sporadic nature of this compli-
cation requires standardized and vigilant follow-up with
postoperative imaging for the life of the patient.2-6 The
long-term success of EVAR therefore depends on con-
scientious patient follow-up.
Clinical trials have shown that the efficacy of EVAR is
comparable with traditional open AAA repair; however,
these trials usually take for granted that patient treatment is
From the Academic Department of Surgery, Greenville Hospital System
University Medical Center.
Competition of interest: none.
Presented at the Southern Association for Vascular Surgery Meeting, Rio
Grande, Puerto Rico, Jan 17-20, 2007.
Correspondence: Spence M. Taylor, MD, Academic Department of Sur-
gery, Greenville Hospital System University Medical Center, 701 Grove
Rd, Greenville, SC 29605 (e-mail: staylor2@ghs.org).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.05.002
434standardized and follow-up is complete.7-9 In reality, 100%
patient follow-up compliance is extraordinarily difficult to
attain; in fact, it has been shown that patients routinely
will resist follow-up evaluation if left to their own de-
sires.10 Investigators of clinical trials have long appreci-
ated this and thus usually recruit special research nurses
and staff dedicated to manage patient follow-up and
study registration. This requires resources not routinely
found in the offices of community-based surgeons in
private practice. This raises a question regarding com-
pleteness of standardized follow-up for EVAR in such
settings. True follow-up compliance rates are not known
in situations devoid of the oversight and management
provided by dedicated research nurses.
The purpose of our study, therefore, was to test the
following hypotheses:
● Post-EVAR follow-up of patients in practice settings
without clinical trials is inferior to follow-up where
patients are enrolled in managed studies,
● Outcomes for patients with incomplete follow-up are
worse than those for patients with frequent follow-up,
and
● Outcomes for patients involved in routine practice
surveillance are inferior to those of patients enrolled in
clinical trials.
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We tested our hypotheses by reviewing the results of
310 consecutive EVARs performed at our institution from
February 1999 to December 2005. Of these, 302 patients
survived and were eligible for follow-up. Table I summa-
rizes the demographics of these 302 patients. Treatment in
47 (15%) of the 302 patients was within the protocol
guidelines of industry-sponsored clinical trials.
All procedures were performed by a fellowship-trained
vascular surgeon or an interventional-trained vascular internist
within the same practicing group of physicians. All patients
whose aneurysms were 5 cm were evaluated for repair.
Patients aged 64 years with anatomy suitable for EVAR
were preferentially offered EVAR. Favorable anatomy for
EVAR included an infrarenal neck15mm, an aortic luminal
diameter27 mm, and aortic angulation60°.
Procedures were performed using a bilateral, trans-
femoral approach in a dedicated operative suite with fixed
fluoroscopic equipment. Intravascular ultrasound (IVUS)
imaging was used to confirm technically successful graft
placement and therapeutic success. The specific type of
graft used was determined by the preference of the attend-
ing physician. All patients were free of type I endoleaks at
the time of discharge.
All patients were prospectively enrolled in a vascular
database at the time of their procedure. The postoperative
follow-up regimen was determined by whether the patient
was enrolled in a clinical trial. Patients not on study proto-
cols were followed up using a postoperative surveillance
regimen of an office visit with imaging at 1 week, 1 month,
every 6 months for 2 years, and then yearly for life. The
importance of follow-up was stressed to each patient before
discharge by the nursing staff and the attending physician.
The initial imagingmodality was duplex ultrasound. All
patients with enlarging aneurysmal sacs or obvious ultra-
sonic flow outside the endoluminal prosthesis underwent
computed tomography (CT) angiography, contrast an-
giography, or both. All endoleaks were preferentially re-
paired using endovascular techniques. Open repair was
used as needed.
Patients in industry sponsored clinical trials were fol-
lowed up in accordance with the individual study protocols.
Follow-up consisted of an abdominal contrast CT scan and
plain abdominal radiographs (flat, upright, lateral, and
oblique) at 1, 6, and 12 months, and then yearly. The
follow-up regimen was generally similar to the regimen just
outlined; however, dedicated clinical trials nurses were
involved to manage the follow-up of each study patient.
Each of the patients in the trials was frequently contacted by
telephone and follow-up compliance was carefully moni-
tored.
For patients not on a study protocol, missed office
appointments were noted by our IDX office software (IDX
Systems Corp, Seattle, Wash) and were rescheduled by
office clerical personnel. If personal verbal communication
was not made, telephone messages were left about a re-
placement appointment. If repeated attempts to obtainoffice follow-up for the patient were unsuccessful, then a
certified letter was mailed to the permanent home address
informing the patient of the need for office follow-up. If the
patient chose not to come for follow-up after delivery of the
certified letter, no further attempts to obtain follow-up
were made.
For those enrolled in a clinical trial, dedicated research
nurses performed all office and diagnostic follow-up sched-
uling. As a general policy, all patients who missed a sched-
uled follow-up appointment were contacted by a research
nurse by telephone. Important clinical information was
gleaned and the need for diagnostic testing and follow-up
stressed. Using this approach, all 47 of the study patients
were in regular telephone contact with the research nurses.
For the purpose of this study, we defined incomplete
follow-up as any patient who missed two or more consec-
utive follow-up office visits. All other patients were defined
as having frequent follow-up. Next, we retrospectively re-
viewed the charts of all 302 patients and determined their
follow-up status. Attempts were made to contact all pa-
tients who were lost to follow-up or whose follow-up care
had been abandoned because of noncompliance by tele-
phone calls and letters. A search was also performed of the
statewide mortality database, the Social Security Death
Index, and the obituary records of local newspapers. These
techniques resulted in follow-up being re-established for all
but 12 of the 302 patients. In the absence of concrete
confirmation of mortality or known complication, these 12
patients were included in the analysis and assumed to be
alive and complication free.
Outcomes for study patients were compared with out-
comes for nonstudy patients, and outcomes for patients
with incomplete follow-up were compared with outcomes
for patients with frequent follow-up. Outcomes examined
were mean follow-up, overall survival, need for reinterven-
tion, minor adverse advents (type I or II endoleak), and
major adverse events, defined as complications where ur-
Table I. Demographics of 302 consecutive endovascular
aneurysm repair patients
Demographic
Value, n or
mean  SD
Age, years (median) 74.7  7.7 (75.5)
Race
White 286
Minority 16
Gender
Male 261
Female 41
Treated in industry-sponsored clinical trial 47
Treated in routine practice 255
Prosthesis used
AneuRx (Medtronic, Minneapolis, Minn) 139
Excluder (W. L. Gore, Flagstaff, Ariz) 130
Zenith (Cook, Bloomington, Ind) 27
Powerlink (Endologix, Irvine, Calif) 6gent operation was required or recommended, including
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prosthesis migration.
Kaplan-Meier life table analysis was performed to cal-
culate survival and time to reintervention. The log-rank test
was used to assess differences in these curves. The Student
t test was used to compare means. Proportions were com-
pared using the Fisher exact test. All analyses were per-
formed using SAS 8 software (SAS, Inc, Cary, NC). Values
of P  .05 were considered indicative of statistical signifi-
cance.
RESULTS
The overall mean follow-up for all patients was 29.6 
22.3 months (median, 26 months). The mean follow-up
for patients in the frequent follow-up group was 34.7 22
months and the mean follow-up for the incomplete
follow-up group was 18.8  18.6 months (P  .001). For
the entire series, endoleaks developed in 39 patients
(12.9%), 41 patients (13.5%) required reintervention
(angio/coil, n 23; open repair, n 7; proximal extender,
n  4; distal cuff, n  3; miscellaneous interventions,
n  4), and a major complication developed in seven
patients (2.3%), three of which resulted in death. Table II
summarizes the types of device used and the complications
by device. The major complications and outcomes are
summarized in Table III.
As defined by the study, frequent follow-up was
achieved in 203 (67.2%) of the 302 patients analyzed, and
99 (32.8%) received incomplete follow-up. Frequent
Table II. The types of devices and the number of complic
Follow-up, n (%)
SFrequent Incomplete
Patient total 203 99
AneuRx* 90 (44.3) 49 (49.5)
Excluder† 88 (43.4) 42 (42.4)
Zenith‡ 21 (10.3) 6 (6.1)
Endologix§ 4 (2.0) 2 (2.0)
*Medtronic, Minneapolis, Minn.
†W. L. Gore, Flagstaff, Ariz.
‡Cook, Bloomington, Ind.
§Endologix, Irvine, Calif.
Table III. Seven major complications occurring in 302 en
Complication Months after EVAR
Acute rupture 79
Acute rupture 40
Acute rupture 61
Acute aneurysm expansion 72
Aortoduodenal fistula 33
Symptomatic graft migration 34
Graft infection 58
EVAR, Endovascular aneurysm repair.follow-upwas achieved in 169 (66.3%) of the 255 nonstudypatients, and 86 (33.7%) had incomplete follow-up. Of the
47 study patients, 34 (72.3%) achieved frequent follow-up,
and 13 (27.7%) experienced incomplete follow-up. A total
of 52 patients had EVAR 1 year (1 study patient, 51
nonstudy patients; 46 patients with frequent follow-up,
and 6 with incomplete follow-up). No patients in the study
or nonstudy cohort failed to keep at least one follow-up
visit. Patients who received EVAR were typically older
patients (71 were octogenarians), some of whom lived in
assisted-living facilities.
The Greenville Hospital System University Medical
Center is a tertiary facility serving a catch area of 1.2 million
people. More than 90% of EVAR patients resided 50
miles of the hospital.
Although the follow-up rate for nonstudy patients
compared with study patients was not statistically different
(P .5), the mean follow-up was better in the study group
patients than in the nonstudy group patients (44.8  23.7
months vs 26.8 20.9 months, P .001). Of the 13 study
patients defined as having incomplete follow-up, 10 were
patients who were in regular contact with the research
nurses by phone but who were physically and logistically
unable to return for regular outpatient evaluation or out-
patient testing. One patient remained in regular contact
with the research nurses by phone but simply refused to
come for follow-up. The two remaining patients were lost
after the clinical trial closed.
In examining the outcomes of patients with incomplete
follow-up compared with patients with frequent follow-up,
s by device
, n (%) Nonstudy, n (%) Complications, n (%)
7 255 7
0.0) 139 (54.5) 5 (71.4)
87.2) 89 (34.9) 2 (28.6)
0.0) 27 (10.6) 0 (0.0)
12.8) 0 (0.0) 0 (0.0)
scular aneurysm repairs
Intervention Outcome
Open repair Death
Attempted endo repair/open repair Death
Open repair Survived
Open repair Death
Open repair Survived
Endo repair Survived
None (patient refusal) Survivedation
tudy
4
0 (
41 (
0 (
6 (dovano statistically significant difference was found in survival
ashed
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known endoleak was statistically similar as well, at 30
(14.8%) for frequent follow-up patients vs nine (9.1%) for
incomplete follow-up patients (P .2). However, patients
with incomplete follow-up experienced a significantly
higher rate of late major complications (n  1 [0.5%] for
frequent follow-up vs n 6 [6.1%] for incomplete follow-up;
P  .006).
In examining the outcomes of study patients compared
with nonstudy patients, no statistically significant difference
was found in survival (Fig 1) or need for reintervention (Fig
2). The incidence of known endoleak was statistically sim-
ilar as well, at 33 (12.9%) for nonstudy patients vs six
(12.8%) for study patients (P 1). Although the incidence
of major complication was similar in both groups, at 2.4%
for the nonstudy group (n  6) vs 2.1% (n  1; P  1), it
is important to note that the only major complication in the
study group occurred in a patient who became lost to
follow-up after the protocol-mandated follow-up ceased.
This patient required emergency open operation for acute
aneurysmal expansion from a presumed endoleak and sub-
sequently died.
Eight aneurysm-related deaths (2.6%) occurred. One
study patient (2.4%) and four nonstudy patients (1.6%)
died 30 days of repair. Although only one study patient
(2.4%) and 2 nonstudy patients (0.8%) died of late compli-
cations related to their aneurysm, it should be noted that
Fig 1. Upper graph, Survival for patients in a clinical
(lower graph) for patients with incomplete follow-up (deach of these patients had incomplete follow-up.DISCUSSION
EVAR has become a mainstay in the arsenal of the
vascular surgeon. Studies have established EVAR efficacy to
be comparable with traditional open AAA repair.11-13
However, known postoperative complications of EVAR,
including endoleak, graft migration and failure, and persis-
tent increase in aneurysmal diameter—which can cause
rupture—must be identified by obligatory postprocedural
follow-up imaging surveillance.2,9,14,15 Although studies
have demonstrated that vigilant postoperative surveillance
can adequately detect late postoperative complications con-
sequent to EVAR, resources associated with such rigorous
surveillance protocols are not routinely available to the
practicing vascular surgeon not participating in clinical
trials.7,15 The obvious question then arises: can the typical
practicing vascular surgeon, working to minimize overhead
costs, achieve comparable follow-up to that of the pub-
lished trials? If not, then what is the impact of incomplete
follow-up?
The issue of post-EVAR follow-up protocol compliance
has received little attention in the literature. For example, the
original studies by Zarins et al16 examining the outcomes after
placement of the AneuRx (Medtronic, Minneapolis, Minn)
endoluminal aortic prosthesis failed to address patients lost to
follow-up and inferred that complete 4-year follow-up was
obtained for all 1192 patients enrolled in the trial. The out-
comes of this study launched thewholesale use of the AneuRx
solid line) vs those in routine practice (dashed line) and
line) vs those with frequent follow-up (solid line).trial (device into clinical practice.
d line
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veyed in a study by Leurs et al17 in a study of 4433 patients
who underwent EVAR between 1996 and 2004 in the
European Collaborators on Stent-Graft Techniques for
AAA and Thoracic Aortic Aneurysm and Dissection Repair
(EUROSTAR) trial. Only 35% of patients in this trial
presented for all scheduled appointments. Statistical analy-
sis found that patients with more comorbidities (ie, current
smokers, hyperlipidemia, and general unfitness for open
AAA repair) were more likely to comply with surveillance.
Despite closer follow-up, these patients still had increased
rates of complications and death. Although the authors
questioned the follow-up regimen itself and identified pa-
tient factors associated with poor compliance, they stopped
short of examining the clinical impact of inadequate
follow-up.17 We, therefore, undertook our study to exam-
ine this impact further.
Based on knowledge from literature and our own clin-
ical intuition, we formed three hypotheses:
First, we postulated that study patients in our practice,
because of attention given by the research nurses, had
superior follow-up compared with patients not en-
rolled in clinical trials.
Second, we postulated that patients who were compliant
with frequent follow-up surveillance had superior
outcomes compared with those with incomplete
follow-up.
Third, assuming the first two hypotheses to be true, we
postulated that study patients had superior outcomes
Fig 2. Upper graph, Reintervention for patients in a clin
(lower graph) for patients with incomplete follow-up (solicompared with nonstudy patients.In examining the first hypothesis, we found no signifi-
cant difference in overall follow-up rates for study patients
compared with nonstudy patients. We did, however, find
that study patients had a longer overall mean follow-up
compared with nonstudy patients. It is worth mentioning
that some of our earliest EVAR patients were study pa-
tients, perhaps explaining why mean follow-up was longer
in this group; however, a large number of nonstudy patients
were also operated on early. We believe that the longer
overall mean follow-up is more accurately a reflection of the
diligent persistence of our research nurses than that of
temporal bias.
In contrast, we believe follow-up rates in the study
group were skewed by two patients who maintained fre-
quent follow-up during the surveillance period mandated
by the clinical trial but quit coming for surveillance as soon
as the trial was complete. One of these patients later had a
major adverse event resulting in death.
Of interest was that our clinical trials nurses achieved
100% contact with every study patient during the protocol
follow-up period. For various reasons, there was a group of
study patients who either refused or were logistically unable
to return for follow-up. Despite this, clinical information
was gleaned by the research nursing team that more than
likely resulted in clinical benefit for the patients. This serves
to highlight that patients are sometimes unable or unwill-
ing to participate in their own follow-up even under rigor-
ous circumstances.
In examining our second hypothesis, we found that
ial (dashed line) vs those in routine practice (solid line) and
) vs those with frequent follow-up (dashed line).ical trpatients with incomplete follow-up experienced a signifi-
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tients with frequent follow-up. Patients with incomplete
follow-up had a 6% major complication rate resulting in a
mortality rate of 43%.
In examining our third hypothesis, we could demon-
strate no difference in outcome between the study patients
and the nonstudy patients. Although these findings dis-
proved our third hypothesis, we believe that these same
findings failed to confirm the null hypothesis because of the
unexpected number of study patients in the study group
who had incomplete follow-up.
Our study suggests that “lost to follow-up” is a major
problem for patients undergoing EVAR and demonstrates a
potential unappreciated limitation of this treatment modality.
These findings are concerning, but they could have been
worse. Despite our best efforts, 12 patients were unable to be
located and, for our analysis, were assumed to have no new
adverse events after their last follow-up appointment; how-
ever, one could reasonably speculate that endoleaks developed
in some, and their EVAR-treated aneurysms may have rup-
tured. By assuming that all of these patients had no subse-
quent complications after being lost to follow-up, we are
giving a best-case scenario for the outcomes of these patients.
When taking into consideration that themedian follow-up for
the entire cohort is just more than 2 years, it can be speculated
that our eventual incidence of adverse events will be markedly
different than that depicted by this study.
The implications of this report are that EVAR has been
released as an efficacious therapy from results of clinical
trials that have failed to document risks associated with lack
of patient compliance with life-long surveillance. We were
quite disturbed to learn that one third of our patients, by
definition, received incomplete follow-up. Our findings
imply that there are patients throughout the country who
are not receiving recommended follow-up surveillance and
who are at risk for a major complication. Information from
published clinical studies looking at EVAR fails to empha-
size this as a shortcoming of the treatment.
Although we did not analyze our 99 patients who had
incomplete follow-up to determine characteristics that may
predispose them for follow-upnoncompliance, our studydoes
suggest that patients at risk for poor follow-up should be
identified and advised against EVAR. It may be instructive to
remember that bariatric surgeons have long been sensitive to
the risks associated with treating patients likely to be noncom-
pliant with follow-up. As a consequence, preoperative patient
selection screening and committed life-long follow-up have
proven to be at least as important as the operative procedure
itself for patients withmorbid obesity. Itmaywell be that such
measures should be instituted as part of themandatory overall
EVAR treatment regimen.
The concept of clinical trial bias, where clinical outcome
after treatment is enhanced by the artificial environment cre-
ated by the study itself, is not new. Mor et al10 found that
outcomes can be substantially determined by the intrinsic trial
infrastructure and not the treatment per se. They demon-
strated that availability of a nurse 24 hours a day or that a study
is multicenter or single institutional in nature may highlyinfluence outcome.10 Influence of clinical trials bias on EVAR
outcomes, although a legitimate concern, is undetermined.
Clearly, this phenomenon should be considered whenever
outcomes are being compared for patients treated in dis-
tinctively different environments.
Our study does have several limitations. It is a retro-
spective study, leaving the results open to various selection
biases. The numbers are relatively small, especially in the
study group cohort, which could result in type II statistical
error. Multi-institutional studies are clearly needed to cor-
roborate our findings and to determine which patients are
at particular risk for noncompliance.
CONCLUSION
Approximately one third of all EVARs performed at our
institution had incomplete follow-up. Poor patient compli-
ance with follow-up surveillance was associated with a
statistically significantly higher incidence of major late com-
plications after EVAR. Although outcomes for our patients
involved in clinical trials were similar to those of our non-
study patients, this was likely due to the unexpected lack of
difference in follow-up rates for nonstudy vs study patients.
This report exposes a previously unappreciated potential
limitation of EVAR and suggests that results in published
clinical trials may not represent what is attainable for pa-
tients treated with EVAR in a more casual practice setting.
The necessity of strict adherence to postoperative surveil-
lance protocols needs to be stressed.Although further corrob-
oration is necessary, it can probably be concluded that EVAR
should be avoided in patients likely to be noncompliant with
critical follow-up surveillance protocols.
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Dr R. James Valentine, (Dallas, Tex). I congratulate the
authors on an interesting and provocative study. Endoleaks and
other problems are expected in a minority of patients who have had
endovascular aneurysm repair (EVAR). Most of us have assumed
that patients will be compliant with follow-up as a condition of
placing these devices. In this retrospective study, however, the
authors found that a third of their EVAR patients did not comply
with an established follow-up routine. The authors’ most impor-
tant finding is that there were significantly more major adverse
events in the patients with inadequate follow-up compared to
those with complete follow-up. This clearly demonstrates that the
long-term success of EVAR is dependent on compliance with a
monitoring program. As the authors suggest, these findings might
be representative of a real problem on a national level.
One might object to the notion that the Greenville Hospital
System represents the general practice of vascular surgery in the
US. However, it is difficult to argue with the authors’ conclusion
that long-term follow-up for EVAR is considerably worse outside
of controlled clinical trials. The addition of a full-time clinical
research nurse did not improve the follow-up, so we are left
wondering whether the findings are a function of the patients in
Greenville, South Carolina. This brings me to me first question.
Where did the patients come from? Did distance from home to the
hospital have an impact on follow-up compliance?
The data from the present study are remarkably similar to our
findings in a VA study evaluating compliance with a watchful
waiting program for small aneurysms.1 We found that about a third
of the patients did not return for repeat imaging studies, similar to
the proportion of your patients who were lost to follow-up after
EVAR.My second question is whether we might be able to predict
poor compliance based on behavior before EVAR. Was there any
indication that your patients missed appointments to follow aneu-
rysms when they were smaller?is how are you going to integrate this information into your
practice? Will you try to predict compliance as a condition of
placing EVAR, and do you have any suggestions on how we can
improve the compliance rate in general practice?
DrWesley B. Jones:With respect to the first question of where
the patients come from in our patient population, the majority of our
patients come within a 20-mile radius from our institution, at least
80%. It didn’t appear that distance or geographic location was a factor
in poor follow-up compliance.
With respect to the second question about patients with poor
follow-up compliance in abdominal aortic aneurysms and if there is
anything we could do to predict this poor compliance. Clearly, that
was felt to be the next step from our study, and we didn’t arrange the
study for logistic regression to identify any associated patient variables
that may be associated with poor follow-up compliance. This may
bear a second study from us on this point. The crux of the problem
was asymptomatic patients don’t appear to feel like they need to go to
the doctor and this has been shown time and time again previously.
With respect to the third question of what do we do next and
how are we are going to integrate in our practice. We have
discussed this and we feel that there are two ways to do this. One
may be to take a page from bariatric surgery programs and preop-
eratively screen these patients aggressively for patients that would
be well compliant, and those that we can identify preoperatively as
being poorly compliant we would offer traditional open repair. The
other opportunity would be a postoperative environment that
would foster good follow-up compliance. One might even argue
that financial incentives to the patient, such as breaks in their
insurance costs or some kind of fiscal reward for actively participat-
ing in preventative care, may be an opportunity for improvement.
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In the abdominal aortic aneurysm (AAA) endovascular
repair (EVAR) post-procedural management paradigm, optimal
graft surveillance methods and intervals for individual patientswhat in retrospect prove to be unnecessary, expensive, and
potentially morbid imaging studies, whereas others experience
sometimes catastrophic device-related events between pre-
scribed imaging intervals.
